시장보고서

상품코드

1790177

세포 및 유전자 치료 위탁개발생산 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 서비스별, 적응증별, 모달리티별, 지역별, 부문별 예측(2025-2033년)

Cell & Gene Therapy Contract Research Organizations Market Size, Share & Trends Analysis Report By Type, By Service, By Indication, By Modality, By Region, And Segment Forecasts, 2025 - 2033

발행일: 2025년 07월 | 리서치사:

Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 세포 및 유전자 치료 위탁개발생산 시장 현황 요약

세계 세포 및 유전자 치료 위탁개발생산 시장 규모는 2024년 48억 4,000만 달러로 추정되며, 2033년에는 1,126만 달러에 달할 것으로 예상되며, 2025-2033년 9.89%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 성장의 배경에는 CGT의 임상시험량 증가, 생명공학 기업의 아웃소싱 증가, 규제의 복잡성, 세계 진출 등이 있습니다.

세포 및 유전자 치료 위탁개발생산 산업의 성장은 특히 종양학, 혈액학, 희귀유전질환 분야의 임상 파이프라인의 급속한 확장에 힘입어 성장하고 있습니다. 스폰서들은 CGT 시험의 높은 복잡성, 규제적 압박, 비용 강도로 인해 CRO를 점점 더 많이 이용하고 있습니다. 이러한 치료법은 전문적인 물류, 개별화된 제조 조정, 고도의 데이터 처리 능력이 필요하기 때문에 많은 중소형 생명공학 기업들이 외주화를 선호하고 있습니다. 또한 ATMP의 임상시험계획(IND) 신청이 전 세계적으로 증가함에 따라 약사 지원, 시험 설계, 장기 안전성 모니터링 서비스에 대한 수요가 증가하고 있습니다.

CRISPR과 같은 유전자 편집 플랫폼과 바이러스 및 비바이러스 전달 기술의 개발은 CGT 개발에 변화를 가져왔고, 전문가 주도의 전임상 및 임상 연구 지원의 필요성을 높이고 있습니다. 탐색, 전임상 밸리데이션, 벡터 분석, GMP 컴플라이언스에 걸친 통합 솔루션을 제공하는 CRO의 경쟁력이 강화되고 있습니다. 또한, 자금 조달 증가, 전략적 파트너십, 업계 통합으로 인해 CRO 생태계의 혁신이 급증함에 따라 확장 능력이 강화되고 있습니다. 이러한 생태계 변화로 인해 전문 CRO는 CGT의 승인과 국제 공동 임상시험의 수행을 가속화하는 데 있어 필수적인 파트너로 자리매김하고 있습니다.

부문 대시보드
변동 분석 : 서비스별
시장 규모·동향 분석 : 서비스별, 2021-2033년
프로젝트·임상시험 관리
규제 전략
데이터 관리·메디컬 라이팅
임상 모니터링
품질 관리/GMP 준거
생물 통계학·안전성 모니터링
환자·시설 모집
기술 이전
기타

제6장 세포 및 유전자 치료 위탁개발생산 시장 : 적응증별, 추정·동향 분석

부문 대시보드
변동 분석 : 적응증별
시장 규모·동향 분석 : 적응증별, 2021-2033년
종양학
중추신경계 질환
감염증
면역질환
심혈관질환
호흡기질환
당뇨병
안과
통증 관리
기타

제7장 세포 및 유전자 치료 위탁개발생산 시장 : 모달리티별, 추정·동향 분석

부문 대시보드
변동 분석 : 모달리티별
시장 규모·동향 분석 : 모달리티별, 2021-2033년
세포 치료
유전자 치료
유전자 재조합 세포 치료

제8장 세포 및 유전자 치료 위탁개발생산 시장 : 지역별, 추정·동향 분석

시장 대시보드
세계 시장 현황
시장 규모, 예측과 동향 분석 : 지역별, 2021-2033년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제9장 경쟁 구도

기업 분류
세포 및 유전자 치료 위탁개발생산 시장 점유율 분석(2024년)
기업 개요
- Altasciences
- Allucent
- Labcorp
- Linical
- Medpace
- Thermo Fisher Scientific Inc.
- Precision Medicine Group, LLC.
- QPS Holdings
- Syneos Health
- ICON plc

KSM 25.08.22

Cell & Gene Therapy Contract Research Organizations Market Summary

The global cell & gene therapy contract research organizations market size was estimated at USD 4.84 billion in 2024 and is projected to reach USD 11.26 million by 2033, growing at a CAGR of 9.89% from 2025 to 2033. The growth is due to the rising clinical trial volume in CGT, increased outsourcing by biotech firms, regulatory complexity, and global expansion, among others.

The growth of the cell & gene therapy contract research organizations industry is fueled by the rapid expansion of clinical pipelines, especially in oncology, hematologic, and rare genetic disorders. Sponsors are increasingly turning to CROs due to the high complexity, regulatory scrutiny, and cost intensity of CGT trials. These therapies demand specialized logistics, personalized manufacturing coordination, and sophisticated data handling capabilities that most small to mid-sized biotech firms prefer to outsource. Moreover, the global increase in Investigational New Drug (IND) applications for ATMPs has heightened demand for regulatory support, trial design, and long-term safety monitoring services.

Advancements in gene-editing platforms such as CRISPR and viral and non-viral delivery technologies are transforming CGT development, thereby intensifying the need for expert-led preclinical and clinical research support. CROs offering integrated solutions across discovery, preclinical validation, vector analytics, and GMP compliance are gaining a competitive edge. Additionally, increased funding, strategic partnerships, and industry consolidation have enhanced the CRO ecosystem's capacity to scale with the innovation surge. This ecosystem shift has positioned specialized CROs as essential partners in accelerating CGT approvals and global trial execution.

Global Cell & Gene Therapy Contract Research Organizations Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cell & gene therapy contract research organizations market report based on type, service, indication, modality, and region:

Type Outlook (Revenue, USD Million, 2021 - 2033)
Drug Discovery
- Target Validation
- Lead Identification
- Lead Optimization
Preclinical
Clinical
- Phase I
- Phase II
- Phase III
- Phase IV
Service Outlook (Revenue, USD Million, 2021 - 2033)
Project & Clinical Trial Management
Regulatory Strategy
Data Management & Medical Writing
Clinical Monitoring
Quality Management / GMP Compliance
Biostatistics & Safety Monitoring
Patient & Site Recruitment
Technology Transfer
Others
Indication Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
CNS Disorders
Infectious Diseases
Immunological Disorders
Cardiovascular Diseases
Respiratory Diseases
Diabetes
Ophthalmology
Pain Management
Others
Modality Outlook (Revenue, USD Million, 2021 - 2033)
Cell-Based Therapies
Gene Therapies
Gene-Modified Cell Therapies
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Norway
- Sweden
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Value chain based analysis (Model 2)
- 1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Cell & Gene Therapy Contract Research Organizations Market: Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
3.2. Cell & Gene Therapy Contract Research Organizations Market Dynamics
- 3.2.1. Market Driver Impact Analysis
- 3.2.2. Market Restraint Analysis
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. Cell & Gene Therapy Contract Research Organizations Market: Analysis Tools
- 3.5.1. Porter's Five Forces Analysis
- 3.5.2. PESTEL Analysis

Chapter 4. Cell & Gene Therapy Contract Research Organizations Market: Type Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Cell & Gene Therapy Contract Research Organizations Market Type Movement Analysis
4.3. Global Cell & Gene Therapy Contract Research Organizations Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
4.4. Drug Discovery
- 4.4.1. Drug Discovery Market Estimates and Forecasts, 2021 - 2033 (USD million)
- 4.4.2. Target Validation
  - 4.4.2.1. Target Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3. Lead Identification
  - 4.4.3.1. Lead Identification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.4. Lead Optimization
  - 4.4.4.1. Lead Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Preclinical
- 4.5.1. Preclinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Clinical
- 4.6.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.2. Phase I
  - 4.6.2.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.3. Phase II
  - 4.6.3.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.4. Phase III
  - 4.6.4.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.5. Phase IV
  - 4.6.5.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Cell & Gene Therapy Contract Research Organizations Market: Service Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Cell & Gene Therapy Contract Research Organizations Market Service Movement Analysis
5.3. Global Cell & Gene Therapy Contract Research Organizations Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
5.4. Project & Clinical Trial Management
- 5.4.1. Project & Clinical Trial Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Regulatory Strategy
- 5.5.1. Regulatory Strategy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Data Management & Medical Writing
- 5.6.1. Data Management & Medical Writing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Clinical Monitoring
- 5.7.1. Clinical Monitoring Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Quality Management / GMP Compliance
- 5.8.1. Quality Management / GMP Compliance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.9. Biostatistics & Safety Monitoring
- 5.9.1. Biostatistics & Safety Monitoring Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.10. Patient & Site Recruitment
- 5.10.1. Patient & Site Recruitment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.11. Technology Transfer
- 5.11.1. Technology Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.12. Others
- 5.12.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Cell & Gene Therapy Contract Research Organizations Market: Indication Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Cell & Gene Therapy Contract Research Organizations Market Indication Movement Analysis
6.3. Global Cell & Gene Therapy Contract Research Organizations Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
6.4. Oncology
- 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. CNS Disorders
- 6.5.1. CNS Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Infectious Diseases
- 6.6.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Immunological Disorders
- 6.7.1. Immunological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Cardiovascular Diseases
- 6.8.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.9. Respiratory Diseases
- 6.9.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.10. Diabetes
- 6.10.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.11. Ophthalmology
- 6.11.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.12. Pain Management
- 6.12.1. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.13. Others
- 6.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Cell & Gene Therapy Contract Research Organizations Market: Modality Estimates & Trend Analysis

7.1. Segment Dashboard
7.2. Global Cell & Gene Therapy Contract Research Organizations Market Modality Movement Analysis
7.3. Global Cell & Gene Therapy Contract Research Organizations Market Size & Trend Analysis, by Modality, 2021 to 2033 (USD Million)
7.4. Cell-Based Therapies
- 7.4.1. Cell-Based Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Gene Therapies
- 7.5.1. Gene Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Gene-Modified Cell Therapies
- 7.6.1. Gene-Modified Cell Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Cell & Gene Therapy Contract Research Organizations Market: Regional Estimates & Trend Analysis by Type, Product, Test, Sample, End Use

8.1. Regional Market Dashboard
8.2. Global Regional Market Snapshot
8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
8.4. North America
- 8.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.2. U.S.
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Competitive Scenario
  - 8.4.2.3. Regulatory Framework
  - 8.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Canada
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Competitive Scenario
  - 8.4.3.3. Regulatory Framework
  - 8.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. Mexico
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Competitive Scenario
  - 8.4.4.3. Regulatory Framework
  - 8.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Europe
- 8.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. UK
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Competitive Scenario
  - 8.5.2.3. Regulatory Framework
  - 8.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Germany
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Competitive Scenario
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. France
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Competitive Scenario
  - 8.5.4.3. Regulatory Framework
  - 8.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Italy
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. Competitive Scenario
  - 8.5.5.3. Regulatory Framework
  - 8.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. Spain
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. Competitive Scenario
  - 8.5.6.3. Regulatory Framework
  - 8.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. Denmark
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. Competitive Scenario
  - 8.5.7.3. Regulatory Framework
  - 8.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.8. Sweden
  - 8.5.8.1. Key Country Dynamics
  - 8.5.8.2. Competitive Scenario
  - 8.5.8.3. Regulatory Framework
  - 8.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.9. Norway
  - 8.5.9.1. Key Country Dynamics
  - 8.5.9.2. Competitive Scenario
  - 8.5.9.3. Regulatory Framework
  - 8.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Asia Pacific
- 8.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Japan
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Competitive Scenario
  - 8.6.2.3. Regulatory Framework
  - 8.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. China
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Competitive Scenario
  - 8.6.3.3. Regulatory Framework
  - 8.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.4. India
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. Competitive Scenario
  - 8.6.4.3. Regulatory Framework
  - 8.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.5. Australia
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. Competitive Scenario
  - 8.6.5.3. Regulatory Framework
  - 8.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.6. South Korea
  - 8.6.6.1. Key Country Dynamics
  - 8.6.6.2. Competitive Scenario
  - 8.6.6.3. Regulatory Framework
  - 8.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.7. Thailand
  - 8.6.7.1. Key Country Dynamics
  - 8.6.7.2. Competitive Scenario
  - 8.6.7.3. Regulatory Framework
  - 8.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Latin America
- 8.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. Brazil
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. Competitive Scenario
  - 8.7.2.3. Regulatory Framework
  - 8.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. Argentina
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. Competitive Scenario
  - 8.7.3.3. Regulatory Framework
  - 8.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. MEA
- 8.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.2. South Africa
  - 8.8.2.1. Key Country Dynamics
  - 8.8.2.2. Competitive Scenario
  - 8.8.2.3. Regulatory Framework
  - 8.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.3. Saudi Arabia
  - 8.8.3.1. Key Country Dynamics
  - 8.8.3.2. Competitive Scenario
  - 8.8.3.3. Regulatory Framework
  - 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.4. UAE
  - 8.8.4.1. Key Country Dynamics
  - 8.8.4.2. Competitive Scenario
  - 8.8.4.3. Regulatory Framework
  - 8.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.5. Kuwait
  - 8.8.5.1. Key Country Dynamics
  - 8.8.5.2. Competitive Scenario
  - 8.8.5.3. Regulatory Framework
  - 8.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Company Categorization
9.2. Cell & Gene Therapy Contract Research Organizations Market Share Analysis, 2024
9.3. Company Profiles
- 9.3.1. Altasciences
  - 9.3.1.1. Company overview
  - 9.3.1.2. Financial performance
  - 9.3.1.3. Product benchmarking
  - 9.3.1.4. Strategic initiatives
- 9.3.2. Allucent
  - 9.3.2.1. Company overview
  - 9.3.2.2. Financial performance
  - 9.3.2.3. Product benchmarking
  - 9.3.2.4. Strategic initiatives
- 9.3.3. Labcorp
  - 9.3.3.1. Company overview
  - 9.3.3.2. Financial performance
  - 9.3.3.3. Product benchmarking
  - 9.3.3.4. Strategic initiatives
- 9.3.4. Linical
  - 9.3.4.1. Company overview
  - 9.3.4.2. Financial performance
  - 9.3.4.3. Product benchmarking
  - 9.3.4.4. Strategic initiatives
- 9.3.5. Medpace
  - 9.3.5.1. Company overview
  - 9.3.5.2. Financial performance
  - 9.3.5.3. Product benchmarking
  - 9.3.5.4. Strategic initiatives
- 9.3.6. Thermo Fisher Scientific Inc.
  - 9.3.6.1. Company overview
  - 9.3.6.2. Financial performance
  - 9.3.6.3. Product benchmarking
  - 9.3.6.4. Strategic initiatives
- 9.3.7. Precision Medicine Group, LLC.
  - 9.3.7.1. Company overview
  - 9.3.7.2. Financial performance
  - 9.3.7.3. Product benchmarking
  - 9.3.7.4. Strategic initiatives
- 9.3.8. QPS Holdings
  - 9.3.8.1. Company overview
  - 9.3.8.2. Financial performance
  - 9.3.8.3. Product benchmarking
  - 9.3.8.4. Strategic initiatives
- 9.3.9. Syneos Health
  - 9.3.9.1. Company overview
  - 9.3.9.2. Financial performance
  - 9.3.9.3. Product benchmarking
  - 9.3.9.4. Strategic initiatives
- 9.3.10. ICON plc
  - 9.3.10.1. Company overview
  - 9.3.10.2. Financial performance
  - 9.3.10.3. Product benchmarking
  - 9.3.10.4. Strategic initiatives